Tetra Radar · FDA Approvals · Decision date
DNL310: FDA decision date
Denali Therapeutics Inc (DNLI) · 5 April 2026
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome.
Source: 8-K of 26 February 2026
The FDA approved it on 24 March 2026.
The FDA approved AVLAYAH to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Denali Therapeutics Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.